Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Sep;35(9):1409-14.
doi: 10.1007/s00264-010-1062-0. Epub 2010 Jun 13.

Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients

Rui Luo  1 , Gang Liu, Wei Liu, Fuxing Pei, Zongke Zhou, Jian Li, Bin Shen, Pengde Kang, Qibing Xie, Xin Ma
Affiliations
Randomized Controlled Trial

Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients

Rui Luo et al. Int Orthop. 2011 Sep.

Abstract

The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease. Adults (n = 168) with Kashin-Beck disease were randomised in clusters to receive six week courses of celecoxib 200 mg once daily, meloxicam 7.5 mg once daily or paracetamol 300 mg three times daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Celecoxib and meloxicam were efficacious in relieving pain and improving stiffness, but unable to improve physical function after six weeks. Paracetamol was efficacious in relieving pain, but unable to improve morning stiffness and physical function after six weeks. Celecoxib and meloxicam provide predictable and sustained relief from pain and stiffness. Paracetamol can relieve the pain. None of the treatments improved impaired physical function in Kashin-Beck disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
WOMAC pain subscale scores at baseline and week 6. C celecoxib, M meloxicam, P paracetamol
Fig. 2
Fig. 2
WOMAC physical function subscale scores at baseline and week 6. C celecoxib, M meloxicam, P paracetamol
Fig. 3
Fig. 3
WOMAC stiffness subscale scores at baseline and week 6. C celecoxib, M meloxicam, P paracetamol
See this image and copyright information in PMC

References

    1. Yang C, Niu C, Bodo M, Gabriel E, Notbohm H, Wolf E, Müller PK. Fulvic acid supplementation and selenium deficiency disturb the structural integrity of mouse skeletal tissue. An animal model to study the molecular defects of Kashin-Beck disease. Biochem J. 1993;289(Pt 3):829–835. - PMC - PubMed
    1. Wang Y, Yang Z, Gilula LA, Zhu C. Kashin-Beck disease: radiographic appearance in the hands and wrists. Radiology. 1996;201:265–270. - PubMed
    1. Chasseur C, Suetens C, Nolard N, Begaux F, Haubruge E. Fungal contamination in barley and Kashin-Beck disease in Tibet. Lancet. 1997;350:1074. doi: 10.1016/S0140-6736(05)70453-0. - DOI - PubMed
    1. Haubruge E, Chasseur C, Debouck C, Begaux F, Suetens C, Mathieu F, Michel V, Gaspar C, Rooze M, Hinsenkamp M, Gillet P, Nolard N, Lognay G. The prevalence of mycotoxins in Kashin-Beck disease. Int Orthop. 2001;25:159–161. doi: 10.1007/s002640100240. - DOI - PMC - PubMed
    1. Moreno-Reyes R, Suetens C, Mathieu F, Begaux F, Zhu D, Rivera MT, Boelaert M, Nève J, Perlmutter N, Vanderpas J. Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status. N Engl J Med. 1998;339:1112–1120. doi: 10.1056/NEJM199810153391604. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources